secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-05-21T21:06:52+00:00
Accession:  0001193125-26-234858
Event type: regulatory
Sentiment:  positive
Materiality: 0.20
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics regains Nasdaq listing compliance via equity alternative
----------------------------------------------------------------------------

- Company had been notified of MVLS deficiency on March 17, 2026.
- On May 20, 2026, Staff confirmed compliance based on Q1 2026 stockholders' equity of $15.672M under Rule 5450(b)(1)(A).
- Matter is now closed; no further action required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526234858/0001193125-26-234858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526234858/d139014d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-234858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer